# Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI

Study · id `cardio:ct-nct05982470` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05982470](<https://clinicaltrials.gov/study/NCT05982470>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05982470

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 328 participants.

## Technical summary

Registry record NCT05982470. Randomized; quadruple masking; primary purpose treatment. Start 2023-08-18 (anticipated); primary completion 2025-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 328 participants (planned count; ClinicalTrials.gov record NCT05982470, source copy `cardio:ctgov-nct05982470-2023-08-08`, retrieved 2026-11-18)
- Planned start: 2023-08-18 (anticipated) (ClinicalTrials.gov record NCT05982470, source copy `cardio:ctgov-nct05982470-2023-08-08`, retrieved 2026-11-18)
- Primary completion: 2025-06-01 (anticipated) (ClinicalTrials.gov record NCT05982470, source copy `cardio:ctgov-nct05982470-2023-08-08`, retrieved 2026-11-18)
- Completion: 2025-10-01 (anticipated) (ClinicalTrials.gov record NCT05982470, source copy `cardio:ctgov-nct05982470-2023-08-08`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT05982470, source copy `cardio:ctgov-nct05982470-2023-08-08`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05982470-2023-08-08`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI
- Acronym: MIRACLE
- Condition: Cerebral Small Vessel Diseases
- Condition: Postmenopausal Symptoms
- Condition: Mild Cognitive Impairment
- Condition: White Matter Hyperintensity
- Intervention (Drug): Estradiol Gel
- Intervention (Drug): Estradiol Placebo Gel
- Intervention (Drug): Progesterone Soft Capsule
- Intervention (Drug): Progesterone Placebo Soft Capsule
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 42eacdd34aa3b527406c266286256d35f768f23e832f8fad79ce725e64872c1b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
